Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Dr. Leon Ferre on the Results of the Randomized Trial of Oxybutynin for Hot Flashes
December 7th 2018Roberto A. Leon Ferre, MD, oncologist, Mayo Clinic, discusses the randomized trial evaluating the effectiveness of oxybutynin chloride in the management of hot flashes in patients with breast cancer at the 2018 San Antonio Breast Cancer Symposium.
Extended PFS Observed in Alpelisib Combo for PIK3CA-Mutant Breast Cancer
Additional analyses from the SOLAR-1 study show that alpelisib, an investigational alpha-specific PI3K inhibitor, combined with fulvestrant extended progression-free survival compared with fulvestrant alone in patients with PIK3CA-mutant advanced breast cancer regardless of line of therapy or prior CDK4/6 inhibitor treatment.
HER3-Targeting Antibody-Drug Conjugate Shows Encouraging Activity in Advanced Breast Cancer
U3-1402, an investigational antibody-drug conjugate targeting HER3, induced objective response in more than 40% of heavily pretreated patients with HER3-expressing breast cancer.
Axillary Radiotherapy Alternative to Lymph Node Dissection in Early-Stage Breast Cancer
Axillary radiotherapy was associated with locoregional control comparable to that with axillary lymph node dissection in patients with early-stage breast cancer who had a positive sentinel lymph node biopsy.
Myelopreservation Possible With CDK4/6 Inhibitor Trilaciclib in TNBC
A longer duration of chemotherapy exposure was possible in patients with metastatic triple-negative breast cancer who received trilaciclib, an investigational CDK4/6 inhibitor, in addition to gemcitabine and carboplatin (GC) compared with GC alone.
Lower-Dose Tamoxifen Reduces Recurrence Risk, Toxicity Incidence in Breast Cancer
December 7th 2018The use of low-dose tamoxifen was shown to significantly reduce the risk of new and recurrent disease following surgery in women diagnosed with breast intraepithelial neoplasia but it did not cause more serious adverse events compared with placebo.
CTC Counts Demonstrate Selection Value in Metastatic Breast Cancer
The use of circulating tumor-cell counts demonstrated strong value for selecting endocrine therapy versus chemotherapy for patients with estrogen receptor–positive, HER2-negative metastatic breast cancer.
Dr. Bidard on the Clinical Utility of Circulating Tumor Cell Count in Breast Cancer
December 6th 2018Francois-Clement Bidard, MD, PhD, professor, medical oncologist, Institut Curie, discusses the clinical utility of circulating tumor cell count (CTC) in breast cancer at the 2018 San Antonio Breast Cancer Symposium.
PD-L1 Immune Cell Expression Critical to Atezolizumab Efficacy in TNBC
Improvements observed in progression-free survival and overall survival with the addition of first-line atezolizumab to nab-paclitaxel in patients with metastatic triple negative breast cancer or inoperable locally advanced TNBC are exclusive to those patients with PD-L1 expression ≥1% in immune cells.
Earlier Adjuvant Chemotherapy Benefits Patients With TNBC
Delayed treatment with chemotherapy of more than 30 days after surgery for patients with triple-negative breast cancer is associated with worse survival rates and outcomes than those who receive adjuvant chemotherapy within 30 days of their procedure.
Dr. Litton on a Study of Neoadjuvant Talazoparib for Patients With BRCA-Mutated TNBC
December 6th 2018Jennifer Litton, MD, associate professor in the Department of Breast Medical Oncology at The University of Texas MD Anderson Cancer Center, discusses a neoadjuvant study of talazoparib (Talzenna) for patients with BRCA1/2 mutated triple-negative breast cancer (TNBC) during the 2018 San Antonio Breast Cancer Symposium.
Dr. Hershman on Adherence to Cardiovascular Medication and Cardiovascular Events in Breast Cancer
December 6th 2018Dawn Hershman, MD, MS, professor of Medicine and Epidemiology, Columbia University Medical Center, leader of the breast cancer program at NewYork-Presbyterian/Columbia University Irving Medical Center, discusses the association between cardiovascular medication and cardiovascular events following a diagnosis of early-stage breast cancer during the 2018 San Antonio Breast Cancer Symposium.
No Survival Benefit With Adjuvant Capecitabine in Early-Stage TNBC
December 6th 2018Adjuvant treatment with capecitabine in patients with early-stage triple-negative breast cancer did not significantly improve disease-free or overall survival compared with observation, according to results from the phase III GEICAM/CIBOMA trial that were presented at the 2018 San Antonio Breast Cancer Symposium.
T-DM1 Likely New Adjuvant Standard in High-Risk HER2+ Breast Cancer
December 6th 2018Ado-trastuzumab emtansine reduced the risk of invasive disease recurrence or death by 50% compared with trastuzumab as an adjuvant treatment for patients with HER2-positive early breast cancer who had residual invasive disease following neoadjuvant therapy.
Venetoclax/Rituximab Combo Achieves Durable, High MRD-Negative Status in CLL
The combination of venetoclax and rituximab for relapsed/refractor chronic lymphoblastic leukemia produced high rates of undetectable minimal residual disease, which was associated with prolonged progression-free survival, a new analysis of a randomized trial showed.
Daratumumab Plus Rd New Frontline Standard in Transplant-Ineligible Myeloma
December 4th 2018The triplet of daratumumab, lenalidomide, and dexamethasone reduced the risk of disease progression or death by 44% compared with lenalidomide plus dexamethasone in newly diagnosed patients with multiple myeloma who were not candidates for high-dose chemotherapy and autologous stem-cell transplant.
High MRD-Negative Rates Seen with Venetoclax in Patients With Relapsed/Refractory CLL
Patients with relapsed/refractory chronic lymphoblastic leukemia treated with single-agent venetoclax attained high rates of minimal residual disease in peripheral blood and bone marrow.
Ibrutinib/Rituximab Improves OS, PFS Versus FCR for Untreated CLL
The combination of ibrutinib and rituximab significantly improved overall survival and progression-free survival compared with standard fludarabine, cyclophosphamide, and rituximab for younger patients with chronic lymphocytic leukemia.
Dr. Poeschel on 6 Versus 4 Cycles of R-CHOP in Frontline DLBCL
December 4th 2018Viola Poeschel, MD, department of hematology, oncology and rheumatology, Saarland University Medical School, Germany, discusses outcomes of patients with diffuse large B-cell lymphoma (DLBCL) who were treated with 4 cycles of R-CHOP during the 2018 ASH Annual Meeting.
Dr. Shah on Initial Results for bb21217 in Multiple Myeloma
December 4th 2018Nina Shah, MD, associate professor of medicine at the University of California, San Francisco Helen Diller Comprehensive Cancer Center, discusses initial results from a phase I clinical trial of bb21217, a next-generation anti-BCMA CAR T-cell therapy, in patients with multiple myeloma during the 2018 ASH Annual Meeting.
Quizartinib Update Presented as FDA Weighs AML Approval
The overall survival benefit with quizartinib in patients with relapsed/refractory FLT3-ITD-mutated acute myeloid leukemia was observed across patient subgroups and reproduced consistently across sensitivity analyses.
Phase III Data Showcase PFS Benefit With Frontline Ibrutinib/Obinutuzumab Combo in High-Risk CLL
December 4th 2018The first-line combination of ibrutinib (Imbruvica) and obinutuzumab (Gazyva) was associated with a 77% reduction in the risk for disease progression or death compared with chemoimmunotherapy in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
